Celgene will have quite a presence at the upcoming American Society of Hematology meeting.
In addition to new data on GvHD, researchers will present very important results from a trial studying use of thalidomide as a treatment for multiple myeloma (an extremely dangerous blood cancer). This is a follow-up study to the smaller, initial study that was presented in Sept. See biz.yahoo.com for info on the initial study.
Here's some info on Monday's presentation (the abstract is at ex2.excerptamedica.com
Abstract #1306 - 8:45, Monday, December 7, 1998 - Room B214-218
TREATMENT OF MULTIPLE MYELOMA
MARKED ANTI-TUMOR EFFECT FROM ANTI-ANGIOGENESIS (AA) THERAPY
WITH THALIDOMIDE (T) IN HIGH RISK REFRACTORY MULTIPLE MYELOMA
(MM)
S. Singhal, J. Mehta, P. Eddlemon*, P. Gray*, J. Cromer*, R. Desikan*, D. Ayers*, D. Siegel, N. Munshi, E. Anaissie, H. Kantarjian, J. Zeldis*, B. Barlogie
Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas; University of Texas MD Anderson Cancer Center, Houston, Texas; Celgene Corporation, Warren, New Jersey, USA
The abstract concludes:
"In conclusion, T [thalidomide] has remarkable anti-tumor activity in advanced and high risk MM, justifying its incorporation into combination chemotherapy trials (D.T. PACE-Dex, T, cisplatin, 1 Adria, CTX, VP16) which has induced 3 true CR's [complete remissions] after
1 cycle among 5 currently evaluable patients."
Rudy |
